Immupharma (#IMM) – “result of WRAP retail offer” brings total raised to approx. £6.5m

Immupharma (#IMM) – potential partnership deal agreement now to extend beyond the end of stated targeted by the end of 2025

ImmuPharma – after ramptastic “Breakthrough Findings into Autoimmune Diseases”, fundraising (natch) and more PR spin…

ImmuPharma (IMM) states that it “is pleased to announce an equity fundraise of c.£2.91 million” including an “oversubscribed” £1.034 million placing at 3.75p per share. Er, how ‘pleasing’ is this to its other shareholders with the shares having been up towards 6p last month?!

Immupharma: “Breakthrough Findings into Autoimmune Diseases” – ‘an undertaking of great advantage, but nobody to know what it is’!?

Immupharma (IMM) has issued a “Breakthrough Findings into Autoimmune Diseases”-titled announcement and the shares have currently responded more than 180% higher to 3.4p and a £14.2 million market cap. So what are the “breakthrough findings” and of what direct financial import are they to the company?

Immupharma (#IMM) – £1.35m shares subscriptions including death spiral, up to £0.5m WRAP retail offer

Immupharma (#IMM) – £0.95m take-up of up to £1.3m broker option at 5p per share

Immupharma (#IMM) – £1.35m placing at 11p per share, £2.2m Lanstead death spiral, all with warrants

Immupharma (#IMM) – had to make ‘variances’ following 2nd September-announced placing

Immupharma (#IMM) – £6.5m placing at 11p per share

Company Becomes a 3-Bagger in 1 Day To Show that Medical Pioneers Can Win Through.

Hello, Share Greeters. One probably goes on a bit too much about one’s long-held belief that a monitor investment in a pocket pharmaceutical venture can reap huge rewards very quickly. At the same time, we must acknowledge that a medical share can fall like a lead anvil from a church tower when, for example, a line of research comes to naught.

Immupharma (#IMM) – £2.66m subscription & “sharing agreement” (subject to adjustment depending on share price) with Lanstead Capital Investors

How A New Cure for Lupus Could Put Big Money in Your Pocket

Hello Share Sloggers. Fancy investing in another AIM-listed company that is pioneering new medical treatments? Yes, I thought you might be a bit wary. But some of these ventures will come up roses, eventually.

A Promising Pocket Pharma Like This Could Pluck Perky Pickings. But You Need Nerve.

Hello, Share Choosers. As we've often said on this glittering website, investing in small drugs companies is fraught with peril. Cures and remedies take ages to develop, and then you have to steer them through a punishing licence minefield. I’m a great believer, though, in this kind of punt, as the world becomes older and less healthy. And investment in the right pharma could reap big rewards for shareholders, but mainly the sick among us. Today’s suggestion seems a more promising pocket pharma than most.

Immupharma (#IMM) raises £3.1m at 26p

Zak Mir's Bull Call of the Day No. 1: Immupharma: Possible Broadening Triangle Rebound

On the face of it you would think that the daily chart of ImmuPharma represents a classic breakdown over recent months, one which would be a falling knife to catch for all but the most brave of bargain hunters.

Immupharma (#IMM) - pays its respects to co-founder and Chairman Richard Warr, who passed away last week

Immupharma (IMM): Reverse H&S Targets 50p Plus

As yet another reminder that technical analysts are not always momentum followers we have the present situation at Immupharma. What can be seen here is that since July last year there has been a descending price channel which has effectively halved the share price from the October peak above 70p. However, we do have near-term positive charting triggers.